Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

Meyer Children's Hospital IRCCS

9 clinical trials · 9 recruiting · OTHER

Meyer Children's Hospital IRCCS has 9 clinical trials registered on ClinicalTrials.gov, with 9 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Meyer Children's Hospital IRCCS\'s Trial Portfolio

Meyer Children's Hospital IRCCS is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

9 of Meyer Children's Hospital IRCCS's 9 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Meyer Children's Hospital IRCCS's research footprint spans Obese Patients (1 trials), hypothalamic-neoplasms (1), and systemic-lupus-erythematosus-of-childhood (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Meyer Children's Hospital IRCCS's portfolio at 56% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Meyer Children's Hospital IRCCS

RECRUITINGNCT07396896

KETO-TUMOR: a Study on Brain Tumors and Central Obesity

Hypothalamic-chiasmatic tumours account for 5-10% of CNS tumours in children and can compromise hypothalamic function, causing alterations in energy balance and weight gain. In...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 301 location
Obese PatientsHypothalamic Neoplasms
RECRUITINGNCT06586710

Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 603 locations
Systemic Lupus Erythematosus of Childhood
RECRUITINGNCT06849622

Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease

Early diagnosis of type 1 diabetes and celiac disease is very useful, allows early therapy and prevents deaths from the onset of diabetic ketoacidosis. This is a pilot study on...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 15001 location
Celiac Disease in ChildrenDiabetes Mellitus, Type IScreening
RECRUITINGNCT07348263

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 2015 locations
Eosinophilic Fasciitis
RECRUITINGNCT07412782

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 1001 location
Osteogenesis ImperfectaOsteoporosisHypogonadisms+6
RECRUITINGNCT07363304

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People...

Cystic Fibrosis (CF) is a genetic disease that affects multiple organs and systems. In recent years, the marketing of CFTR protein modulator drugs, such as the...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 1506 locations
Cystic Fibrosis (CF)
RECRUITINGNCT06856967

Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.

This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 1388 locations
Respiratory Synctial Virus Infections
RECRUITINGNCT06273748

RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age

Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 29019 locations
Uveitis
RECRUITINGNCT07375940

Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease

Behçet disease (BD) is a chronic multisystem inflammatory disorder with a relapsing-remitting course. Pediatric-onset BD is rare and characterized by marked clinical...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 902 locations
Behcet Disease and Vascular Involvement

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Meyer Children's Hospital IRCCS have on ClinicalTrials.gov?

Meyer Children's Hospital IRCCS has 9 clinical trials registered on the federal ClinicalTrials.gov registry, of which 9 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Meyer Children's Hospital IRCCS study?

Meyer Children's Hospital IRCCS's registered trials cover 20 conditions on ClinicalTrials.gov, led by Obese Patients (1 trial), hypothalamic-neoplasms (1 trial), systemic-lupus-erythematosus-of-childhood (1 trial), Celiac Disease in Children (1 trial), diabetes-mellitus-type-i (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Meyer Children's Hospital IRCCS clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 9 trials tracked for Meyer Children's Hospital IRCCS.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.